---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-040608"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T06:15:53.086606+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NRx Pharmaceuticals to effect 1-for-10 reverse stock split effective April 1, 2024 to maintain Nasdaq listing

## Summary
- Reverse stock split at 1:10 ratio; shares outstanding reduced from ~95.7M to ~9.57M.
- Effective at 4:30 p.m. ET on April 1, 2024; trading on split-adjusted basis begins April 2, 2024 under symbol NRXP.
- Fractional shares rounded up to nearest whole share; par value unchanged.
- Chairman cites upcoming clinical trial readouts, planned NDA filing, and dividend of HOPE Therapeutics shares.
- CUSIP changes to 629444209; stockholders need not exchange certificates.

## SEC filing metadata
- accession: 0001104659-24-040608
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.03, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000110465924040608/0001104659-24-040608-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000110465924040608/tm2410082d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-040608
- JSON: https://secwatch.observer/filing/0001104659-24-040608.json
- Plain text: https://secwatch.observer/filing/0001104659-24-040608.txt

## Key facts
- Governance Changes
  NRX Pharmaceuticals, Inc.: Amendment to certificate of incorporation to effect a 1-for-10 reverse stock split of common stock, effective April 1, 2024 (effective 2024-04-01).
  - Change: charter amendment
  - Effective: 2024-04-01
  source text: On March 28, 2024, NRx Pharmaceuticals, Inc. (the “ Company ”) announced that it had filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company’s Second Amended and Restated Certificate of Incorporation (the “ Charter Amendment ”) to effect a 1-for-10 reverse stock split (the “ Reverse Stock Split ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), effective as of 4:30 p.m. Eastern Standard Time on April 1, 2024 (the “ Effective Time ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000110465924040608/0001104659-24-040608-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.